Internal Medicine

Approval of isatuximab-irfc (Sarclisa) was based on the results of a 307-person trial, according to a statement from the FDA.

Everyone has an opinion. But what do the actual experts think?

New data from Brigham and Women's Hospital suggests sleep irregularity could be a risk factor for cardiovascular disease.

Prescriptions for antipsychotic medications are commonly used to treat several different brain disorders.

Analysis of more than 13k patients from Taiwan found a vegetarian diet was linked to a lower risk of incident stroke events later in life.

The expert-led narrative series will seek to answer when and how the development of opioids led to a public health crisis.

Sika Dunyoh, director of education programs with NORD, discusses that year in rare disease and what to expect moving forward.

The RareWear program is designed to bridge medical device companies to rare disease patient applicants, seeking better disease and treatment monitoring.

Advanced cystic fibrosis liver disease manifests as portal hypertension with or without cirrhosis in about 7% of patients with cystic fibrosis.

New research suggests proposals aimed at reducing out of pocket costs may harm minimally-funded drug developers.

An emphasis on collecting and assessing quality-of-life biomarkers shows promise for tailoring treatment of the rare condition.

Investigators in a new study find little difference between cognitive screenings and standard care in limiting emergency department visits from nursing home residents.

Though weekly activity has slowed, experts insist the national activity remains high overall.

Younger hepatitis B patients had better odds at transplant-free survival after 6 months.

A new study examines how different types of chronic conditions were associated with different increases in risk of visual impairment.

Cerebrospinal fluid storage time did not influence the tested biomarker levels in narcolepsy type 1 patients.

A discussion on how to approach the real-world application of bempedoic acid with the Chief of Cardiology at Baylor College of Medicine.

New data shows that baseline severity of depression did not moderate the variability of responses to antidepressants.

The approval is the second non-statin LDL-C lowering therapy from Esperion to receive approval in the month of February.

The task force’s recommendations will remain unchanged since the last version in 2014.

A new algorithm using a 70% training had a 51.7% success rate in predicting individualized treatments for first-episode schizophrenia patients.

Early menopause onset has been linked to increased CVD risk, but a new study from England is examining whether age of onset has a role in worsening risk factors.

A clinical health psychologist discusses how to keep a patient-centered approach for treating chronic pain in today's healthcare environment.

The approval allows Zynex to market CM-1500, a blood monitoring system aimed at helping doctors monitor various patient parameters.

The VistaScan mobile ultrasound platform from Emagine Solutions Technology can be used via an app and connect directly to a clinician's cell phone or tablet.